Entities / Company
Beam Therapeutics.
American healthcare company
- Reports this week
- 0
- Active events
- 0
- Connections
- 35
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Redmile Group LLC trimmed its position in Beam Therapeutics.Some support1 report
-
Cathie Wood has acquired and continues to acquire shares of Beam Therapeutics.Some support1 report
-
Citigroup lifted its price objective and gave a buy rating for Beam Therapeutics, while Bank of America restated its buy rating and set a new price target.Some support4 reports
-
Beam Therapeutics and Prime Medicine are competing for market share in the AATD gene-editing space, with an arbitration ruling favoring Prime's program.Some support1 report
Gone quiet
No new reports in 90+ days-
Sana Biotechnology, based in Seattle, presented promising cell therapy data on July 3, 2025, involving a gene editing system and potential benefits from Trump-era tariffs.Speculative1 report
-
Ashish Gupta, an associate professor at the University of Minnesota, was an investigator in the BEACON trial as of July 3, 2025.Speculative1 report
-
H.C. Wainwright reiterated a Buy rating for Beam Therapeutics on July 6, 2025.Speculative1 report
-
Market expects earnings based on consensus outlook for Beam Therapeutics, announced on July 29, 2025.Some support1 report
-
John Evans was appointed chief executive officer of Beam Therapeutics on August 5, 2025.Some support1 report
-
FDA granted RMAT designation to Beam Therapeutics' drug candidate BEAM-101.Some support2 reports
-
Beam Therapeutics participated in investor conferences held in Boston on August 25, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Beam Therapeutics this week
News at the entities that move Beam Therapeutics most-
Cathie Wood StructuralCathie Wood predicts that Bitcoin's price will reach $2.4 million by 2030.Moves Beam Therapeutics
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Beam Therapeutics
-
Ark Invest TransactionalArk Invest is tokenizing its fund using Securitize infrastructure and making ARKVX available on the Ethereum network.Moves Beam Therapeutics
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Beam Therapeutics
-
Citigroup Mentioned togetherCitigroup provided analyst ratings and targets for Autodesk stock, which trades on Nasdaq.Moves Beam Therapeutics
-
MarketBeat Mentioned togetherApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Beam Therapeutics
Connections
The 10 strongest of 35, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Cathie Wood Structural
Cathie Wood holds and continues to acquire shares in Beam Therapeutics.
-
FDA Structural
The FDA formally regulates Beam Therapeutics and grants critical designations and clearances for its drug candidates.
-
CRISPR Therapeutics Operational
Both companies are actively competing in the gene-editing space, developing therapies for blood disorders.
-
Ark Invest Transactional
Ark Invest is actively purchasing or increasing its investment stake in Beam Therapeutics.
-
SEC Structural
Beam Therapeutics is subject to ongoing regulatory oversight and disclosure requirements mandated by the SEC.
-
Amy Simon Structural
Amy Simon is identified as an insider of Beam Therapeutics, evidenced by the sale of company stock.
-
Bank of America Mentioned together
Bank of America provides financial ratings and price targets for Beam Therapeutics.
-
MarketBeat Mentioned together
MarketBeat aggregates and presents financial data, including analyst ratings and price targets, for Beam Therapeutics.
History
Events by the month they beganJuly 2026
4 events- Redmile Group LLC trimmed its position in Beam Therapeutics.
- Cathie Wood has acquired and continues to acquire shares of Beam Therapeutics.
- Citigroup lifted its price objective and gave a buy rating for Beam Therapeutics, while Bank of America restated its buy rating and set a new price target.
- Beam Therapeutics and Prime Medicine are competing for market share in the AATD gene-editing space, with an arbitration ruling favoring Prime's program.
June 2026
7 events- Sana Biotechnology, based in Seattle, presented promising cell therapy data on July 3, 2025, involving a gene editing system and potential benefits from Trump-era tariffs.
- Ashish Gupta, an associate professor at the University of Minnesota, was an investigator in the BEACON trial as of July 3, 2025.
- H.C. Wainwright reiterated a Buy rating for Beam Therapeutics on July 6, 2025.
- Market expects earnings based on consensus outlook for Beam Therapeutics, announced on July 29, 2025.
- John Evans was appointed chief executive officer of Beam Therapeutics on August 5, 2025.
- FDA granted RMAT designation to Beam Therapeutics' drug candidate BEAM-101.
- Beam Therapeutics participated in investor conferences held in Boston on August 25, 2025.